Karyopharm Therapeutics Inc (OQ:KPTI)

Jul 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 41,700 shares of...
Jun 24, 2020 07:00 am ET
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating XPOVIO in patients with relapsed or...
Jun 22, 2020 11:25 am ET
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of...
Jun 12, 2020 07:00 am ET
Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound,...
Jun 09, 2020 09:00 am ET
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients...
Jun 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of...
May 28, 2020 04:05 pm ET
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- SVd Was Superior to Vd Across Key Secondary Efficacy Endpoints Including Overall Response Rate, Percent of Patients Achieving ≥VGPR and Median Duration of Response -- -- SVd Was Associated with Significantly Lower Rates and Severity of...
May 26, 2020 04:05 pm ET
Karyopharm to Participate at Jefferies Virtual Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on...
May 26, 2020 07:00 am ET
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO®...
May 20, 2020 08:00 am ET
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO®...
May 13, 2020 08:00 am ET
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19...
May 12, 2020 07:00 am ET
Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare...
May 05, 2020 07:00 am ET
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details...
May 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of...
Apr 30, 2020 01:03 pm ET
PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial
PROMETRIKA (www.prometrika.com), a leading clinical research organization, is collaborating with Karyopharm Therapeutics (Nasdaq:
Apr 29, 2020 01:58 pm ET
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the...
Apr 28, 2020 04:05 pm ET
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, May...
Apr 22, 2020 09:08 am ET
Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19
BUDAPEST, Hungary, April 22, 2020 /PRNewswire/ -- Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.  ...
Apr 20, 2020 07:00 am ET
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll...
Apr 07, 2020 07:00 am ET
Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor, marketed as XPOVIO®, is currently approved at...
Apr 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 161,500 shares of...
Mar 17, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyopharm’s common...
Mar 12, 2020 07:00 am ET
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy and...
Mar 09, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shares of...
Mar 06, 2020 04:05 pm ET
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase...
Mar 03, 2020 06:36 pm ET
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock  at a price to the...
Mar 02, 2020 04:01 pm ET
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also...
Mar 02, 2020 07:00 am ET
Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly...
Feb 28, 2020 07:00 am ET
Karyopharm Appoints Richard Paulson to its Board of Directors
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its Board of Directors. Mr. Paulson is currently Executive Vice President and Chief Executive Officer of...
Feb 19, 2020 08:00 am ET
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking accelerated...
Feb 18, 2020 07:00 am ET
Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare...
Feb 13, 2020 07:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2019. In addition, Karyopharm highlighted select corporate milestones,...
Feb 11, 2020 07:00 am ET
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for the commercialization of XPOVIO®...
Feb 06, 2020 07:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13, 2020. Karyopharm's management team will host a...
Feb 03, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 shares of...
Jan 13, 2020 07:00 am ET
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth quarter and full year 2019 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective...
Jan 07, 2020 07:00 am ET
Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January...
Jan 02, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of...
Dec 23, 2019 07:38 am ET
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for XPOVIO®...
Dec 08, 2019 09:00 am ET
Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that four posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and...
Dec 07, 2019 09:00 am ET
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that two presentations highlighting new and updated data relating to  XPOVIO® (selinexor), the Company’s first-in-class, oral Selective...
Dec 02, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 84,000 shares of...
Nov 06, 2019 10:12 am ET
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that thirteen abstracts have been selected for presentation, including one oral presentation, at the upcoming American Society of Hematology...
Nov 04, 2019 07:00 am ET
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the third quarter 2019.  In addition, Karyopharm highlighted select corporate milestones, including an update regarding the...
Nov 01, 2019 04:58 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 169,500 shares of...
Oct 28, 2019 07:00 am ET
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's management team will host a conference call...
Oct 24, 2019 04:04 pm ET
Shareholder Alert: Robbins Arroyo LLP Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act of 1933 for conduct related
Oct 04, 2019 10:00 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc. (NASDAQ: HRTX), Immunomedics, Inc. (NASDAQ: IMMU), and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) on...
Oct 01, 2019 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 130,500 shares of...
Sep 23, 2019 09:19 am ET
CLASS ACTION UPDATE for MMM, KPTI, GTT and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 23, 2019 08:45 am ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 22, 2019 10:50 pm ET
KARYOPHARM 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a...
Sep 21, 2019 10:00 am ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Con
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between March 2, 2017 to February 22, 2019 (the “Class Period”). Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 20, 2019 10:50 pm ET
KARYOPHARM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). Investor losses must relate to purchases of the Company’s shares between March 2, 2017 and February 22, 2019 or issued in connection with its April 2017 or May 2018 public offering. This action is pending in the United States Di
Sep 20, 2019 03:00 pm ET
INVESTOR ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm”  or “the Company”) (NASDAQ:  KPTI) and certain of its officers, on behalf of...
Sep 20, 2019 01:00 pm ET
FINAL SEPT. 23 DEADLINE: GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action – KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 20, 2019 10:04 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Sep 19, 2019 10:00 am ET
FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
NEW YORK, Sept. 19, 2019 /PRNewswire/ -- Attorney Advertising --Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. ("Karyopharm"  or "the Company") (NASDAQ:  KPTI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Karyopharm securities between March 2, 2017 and February 22, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/kpti.  ...
Sep 19, 2019 09:46 am ET
SHAREHOLDER ALERT: LB KPTI EGBN MDP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 18, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 18, 2019 08:21 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Con
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between March 2, 2017 to February 22, 2019 (the "Class Period").  Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit....
Sep 17, 2019 07:44 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Karyopharm Therapeutics Inc. and Certain Officers – KPTI
Pomerantz LLP announces that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) and certain of its officers.   The class action, filed in United States District Court, for the...
Sep 17, 2019 09:58 am ET
CLASS ACTION UPDATE for NFLX, KPTI, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 16, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 -...
Sep 16, 2019 01:30 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI)...
Sep 16, 2019 10:30 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI)...
Sep 16, 2019 08:50 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 16, 2019 07:00 am ET
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing development and...
Sep 13, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 13, 2019 06:30 pm ET
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for XPOVIO™ (selinexor) will be presented at the 17th International Myeloma Workshop (IMW) taking...
Sep 13, 2019 03:00 pm ET
Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 12, 2019 05:05 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action – KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 12, 2019 02:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Sep 12, 2019 09:32 am ET
SHAREHOLDER ALERT: OMCL KPTI NTAP TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 11, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 -...
Sep 11, 2019 09:24 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, KPTI, PS and TXT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 10, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Omnicell, Ideanomics, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Omnicell, Inc. (NASDAQ: OMCL), Ideanomics, Inc. (NASDAQ: IDEX), Eagle Bancorp,  Inc. (NASDAQ: EGBN), and Karyopharm...
Sep 10, 2019 04:30 pm ET
NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Sep 10, 2019 11:01 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc.  To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Sep 10, 2019 09:38 am ET
CLASS ACTION UPDATE for OMCL, KPTI, CURLF and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 09, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 09, 2019 09:40 am ET
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contac
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 06, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period:...
Sep 06, 2019 09:27 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, MNK and CAH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Sep 05, 2019 03:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Sep 05, 2019 10:10 am ET
SHAREHOLDER ALERT: INS KPTI EGBN VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 04, 2019 11:00 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Sep 04, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Sep 04, 2019 03:00 pm ET
NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 04, 2019 09:33 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INS, OMCL, KPTI and CAH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Sep 03, 2019 10:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ideanomics, Eagle Bancorp, Karyopharm Therapeutics, and National General Holdings and Encourages Invest
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Ideanomics, Inc (NASDAQ: IDEX), Eagle Bancorp, Inc. (NASDAQ: EGBN), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), and National...
Sep 03, 2019 09:46 am ET
CLASS ACTION UPDATE for NFLX, KPTI, GVA and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Sep 03, 2019 08:40 am ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Sep 03, 2019 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 39,000 shares of Karyopharm’s...
Sep 02, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 30, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 30, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC – Class Action Update
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 29, 2019 01:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 29, 2019 12:56 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI
Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ: KPTI) investors who purchased securities: (i) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”); (ii) in or traceable to...
Aug 29, 2019 11:28 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 29, 2019 09:14 am ET
SHAREHOLDER ALERT: LB KPTI EVH VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 28, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 28, 2019 09:14 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, JE, GTT and VAL
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 28, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Baird 2019 Global Healthcare...
Aug 27, 2019 09:36 am ET
CLASS ACTION UPDATE for VNTR, KPTI, GTT and VAL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Karyopharm, L Brands, National General, and Mallinckrodt and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), L Brands, Inc. (NYSE: LB), National General Holdings Corp. (NASDAQ: NGHC), and...
Aug 26, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 26, 2019 10:06 pm ET
Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. – KPTI
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit...
Aug 26, 2019 11:35 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 24, 2019 10:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Aug 24, 2019 10:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Aug 23, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 23, 2019 03:00 pm ET
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) – Class Action Reminder – Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Aug 22, 2019 10:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FDX, CTST, KPTI and NGHC
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 21, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 21, 2019 05:20 pm ET
Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the results of the Phase 2b STORM study evaluating XPOVIO™ (selinexor) in patients with heavily pretreated, triple class refractory...
Aug 21, 2019 03:47 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc.  To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 20, 2019 03:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 20, 2019 09:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 19, 2019 10:50 pm ET
Shareholder Alert by Former Louisiana Attorney General: KSF Reminds EGBN, KPTI, LB, NGHC Investors of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 19, 2019 09:42 am ET
CLASS ACTION UPDATE for TEVA, FDX, NFLX and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 18, 2019 07:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ: EGBN), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), L Brands, Inc. (NYSE: LB), and National...
Aug 16, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 15, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 15, 2019 09:29 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, CARB and CAH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Aug 14, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period:...
Aug 14, 2019 11:59 am ET
CLASS ACTION UPDATE for KPTI, NGHC and PS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 13, 2019 09:49 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NFLX, KPTI, NGHC and TWOU
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 12, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 12, 2019 02:16 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 12, 2019 01:20 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 12, 2019 08:54 am ET
CLASS ACTION UPDATE for INS, NFLX, KPTI and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 11, 2019 09:12 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Netflix, EQT, Eagle Bancorp, and Karyopharm and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Netflix, Inc. (NASDAQ: NFLX), EQT Corporation (NYSE: EQT), Eagle Bancorp, Inc. (NASDAQ: EGBN), and Karyopharm Therapeutics,...
Aug 09, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 09, 2019 03:33 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”) of the important September 23, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
Aug 09, 2019 03:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 08, 2019 09:55 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BUD, CTST, OMCL and KPTI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Aug 07, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 06, 2019 03:15 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Aug 06, 2019 09:37 am ET
SHAREHOLDER ALERT: DBD OMCL NFLX KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 06, 2019 07:00 am ET
Karyopharm Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the second quarter 2019.  In addition, Karyopharm highlighted select corporate milestones, including an update regarding...
Aug 05, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Aug 05, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against EQT Corporation, Eagle Bancorp, Karyopharm, and L Brands, Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of EQT Corporation, Eagle Bancorp, Inc., Karyopharm Therapeutics, Inc., and L Brands, Inc. Stockholders have until the deadlines...
Aug 05, 2019 06:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Aug 05, 2019 06:04 pm ET
CLASS ACTION UPDATE for RMED, OMCL, KPTI and CURLF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 05, 2019 02:35 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Aug 05, 2019 09:19 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BOX, RLGY, KPTI and CARB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Aug 02, 2019 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN)Class Period: 3/2/2015 - 7/17/2019Lead Plaintiff Motion Deadline: September...
Aug 02, 2019 06:08 pm ET
ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPT
NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws....
Aug 02, 2019 04:18 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ:
Aug 02, 2019 03:00 pm ET
SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm”  or “the Company”) (NASDAQ:  KPTI) and certain of its officers, on behalf of...
Aug 02, 2019 02:54 pm ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, Aug. 2, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as...
Aug 02, 2019 11:01 am ET
CLASS ACTION UPDATE for VNTR, MMM and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 02, 2019 09:21 am ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against  Karyopharm Therapeutics Inc. – KPTI
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The...
Aug 01, 2019 07:55 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors that: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and Febr
Aug 01, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 67,500 shares of Karyopharm’s...
Aug 01, 2019 12:37 pm ET
CLASS ACTION UPDATE for EROS, OMCL, KPTI and JE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Aug 01, 2019 11:27 am ET
KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to file a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) from March 2, 2017,...
Jul 31, 2019 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS EGBN, KPTI, LB, NGHC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Eagle Bancorp, Inc. (EGBN) Class Period: 3/2/2015...
Jul 31, 2019 05:45 pm ET
Rosen, a Leading Law Firm, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – KPTI
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...
Jul 31, 2019 02:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jul 31, 2019 09:08 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of RMED, CTST, OMCL and KPTI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Jul 30, 2019 07:00 am ET
Karyopharm to Report Second Quarter 2019 Financial Results on August 6, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Karyopharm's management team will host a conference call...
Jul 29, 2019 04:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal...
Jul 29, 2019 12:52 pm ET
Rosen, a Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Karyopharm investors under the federal securities laws.
Jul 29, 2019 09:43 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the...
Jul 29, 2019 09:09 am ET
SHAREHOLDER ALERT: MBNKF RLGY FRED KPTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 26, 2019 10:54 pm ET
KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against
NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI), if they purchased the Company's shares issued in connection with its April 2017 or May 2018 public offering or between March 2, 2017 and February 22, 2019, inclusive (the "Class Period").  This action is pending in the United States District Court for the Di...
Jul 26, 2019 07:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ:
Jul 26, 2019 04:39 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors that: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive (the “Class Period”); (2) purchased Karyopharm share
Jul 26, 2019 03:00 pm ET
SHAREHOLDER ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 23, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) and certain of its officers, on behalf of...
Jul 26, 2019 02:44 pm ET
Robbins Arroyo LLP: Karyopharm Therapeutics Inc. (KPTI) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act of 1933 for conduct related to the com
Jul 26, 2019 01:55 pm ET
CLASS ACTION UPDATE for BUD, OMCL, KPTI and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 26, 2019 01:14 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm
NEW YORK, July 26, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Jul 26, 2019 10:16 am ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Conta
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Jul 26, 2019 09:40 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ASNA, RLGY, LB and KPTI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 25, 2019 11:07 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ:
Jul 25, 2019 09:30 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jul 25, 2019 06:53 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI)
Law Offices of Howard G. Smith announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jul 25, 2019 10:22 am ET
CLASS ACTION UPDATE for TUSK, BOX, PYX and KPTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 25, 2019 10:12 am ET
Karyopharm Therapeutics Shareholder Alert: Kehoe Law Firm, P.C. Investigating Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Kehoe Law Firm, P.C. announces that it is investigating securities claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) to determine whether Karyopharm and certain of its officers or directors...
Jul 24, 2019 11:03 pm ET
KPTI INVESTOR ALERT: Hagens Berman Alerts Investors in Karyopharm Therapeutics (KPTI) Public Offerings to Possible Disclosure Violations
SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.'s (NASDAQ: KPTI) April 28, 2017 and May 7, 2018 public offerings to the firm's investigation into possible securities law violations....
Jul 24, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between...
Jul 24, 2019 08:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics Inc. (KPTI)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (Nasdaq: KPTI) in the United States District Court for the District of Massachusetts on behalf of...
Jul 24, 2019 01:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jul 24, 2019 01:12 pm ET
KPTI CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit has Been Filed Against Karyopharm Therapeutics Inc.
NEW YORK, July 24, 2019 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI) from March 2, 2017, through February 22, 2019 (the "Class Period"). The lawsuit, filed in the United States District Court for the District of Massachusetts, seeks to recover Karyopharm shareholders' investment losses under the Securities Act of 1933 and the Securities Exchange Act of 1934....
Jul 23, 2019 06:52 pm ET
Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwrite
NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI), and certain of the Company's senior executives, Karyopharm's Board of Directors, and the underwriters of the Offerings, (collectively, "Defendants").  The action, which is captioned Allegheny County Employees' Retirement System v. Karyopharm Therapeutics Inc., No. 1:19...
Jul 05, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Karyopharm Therapeutics, Northstar Realty, or Tyme Technologies?
NEW YORK, July 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, KPTI, NRE, and TYME....
Jul 03, 2019 01:06 pm ET
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with...
Jun 28, 2019 04:37 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,500 shares of Karyopharm’s...
Jun 19, 2019 11:05 am ET
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company’s first-in-class,...
Jun 14, 2019 07:00 am ET
 Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced three presentations highlighting new and updated data from the Phase 1b/2 STOMP (Selinexor and Backbone Treatments of Multiple Myeloma Patients)...
Jun 03, 2019 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 95,500 shares of Karyopharm’s...
May 28, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Jefferies 2019 Global Healthcare...
May 16, 2019 11:06 am ET
Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts relating to selinexor, the Company’s first in class, oral SINE compound, will be presented at the upcoming European Hematology...
May 15, 2019 07:00 am ET
Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, congratulates its founder, President and Chief Scientific Officer, Sharon Shacham, PhD, MBA, for winning the esteemed New York Intellectual Property Law...
May 09, 2019 07:02 am ET
Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2019 and provided an overview of recent accomplishments and clinical development progress for its innovative...
May 08, 2019 07:00 am ET
Karyopharm to Participate in Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences:  The Bank of America Merrill Lynch Health Care...
May 02, 2019 07:00 am ET
Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2019 financial results on Thursday, May 9, 2019. Karyopharm's management team will host a conference call and...